Growth in global diabetic neuropathy market is highly attributed to consistently increasing diabetic population across the globe linked with growing awareness among people is considered as major market driver for diabetic neuropathy market. Moreover, global market is primarily driven by changing lifestyle which has mostly resulted into unhealthy dietary habits and patterns. In addition, factors such as increasing aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes, and rise in R & D activities in drug discovery and development have contributed in the global growth. However, growth of this market is predominantly restrained by longer approval time for drugs and side effects and rising cost of diabetic neuropathy treatment. Also, stringent regulatory requirement and significant failure rate during the clinical trials expected to be the growth barriers in the years to come.
The global Diabetic Neuropathy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Diabetic Neuropathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Neuropathy.
Report Scope
The Diabetic Neuropathy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetic Neuropathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Neuropathy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Janssen Pharmaceuticals
Eli Lilly and Company
ACTAVIS
Cephalon
MEDA Pharma & Co. KG
GlaxoSmithKline
NeuroMetrix
Johnson & Johnson Services, Inc.
Novartis AG
DAIICHI SANKYO
Segment by Type
Oral
Subcutaneous
Intravenous
Segment by Application
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Neuropathy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Neuropathy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Subcutaneous
1.2.4 Intravenous
1.3 Market by Application
1.3.1 Global Diabetic Neuropathy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Online Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Neuropathy Market Perspective (2019-2030)
2.2 Diabetic Neuropathy Growth Trends by Region
2.2.1 Global Diabetic Neuropathy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Diabetic Neuropathy Historic Market Size by Region (2019-2024)
2.2.3 Diabetic Neuropathy Forecasted Market Size by Region (2025-2030)
2.3 Diabetic Neuropathy Market Dynamics
2.3.1 Diabetic Neuropathy Industry Trends
2.3.2 Diabetic Neuropathy Market Drivers
2.3.3 Diabetic Neuropathy Market Challenges
2.3.4 Diabetic Neuropathy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Neuropathy Players by Revenue
3.1.1 Global Top Diabetic Neuropathy Players by Revenue (2019-2024)
3.1.2 Global Diabetic Neuropathy Revenue Market Share by Players (2019-2024)
3.2 Global Diabetic Neuropathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetic Neuropathy Revenue
3.4 Global Diabetic Neuropathy Market Concentration Ratio
3.4.1 Global Diabetic Neuropathy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Neuropathy Revenue in 2023
3.5 Diabetic Neuropathy Key Players Head office and Area Served
3.6 Key Players Diabetic Neuropathy Product Solution and Service
3.7 Date of Enter into Diabetic Neuropathy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Neuropathy Breakdown Data by Type
4.1 Global Diabetic Neuropathy Historic Market Size by Type (2019-2024)
4.2 Global Diabetic Neuropathy Forecasted Market Size by Type (2025-2030)
5 Diabetic Neuropathy Breakdown Data by Application
5.1 Global Diabetic Neuropathy Historic Market Size by Application (2019-2024)
5.2 Global Diabetic Neuropathy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Diabetic Neuropathy Market Size (2019-2030)
6.2 North America Diabetic Neuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Diabetic Neuropathy Market Size by Country (2019-2024)
6.4 North America Diabetic Neuropathy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diabetic Neuropathy Market Size (2019-2030)
7.2 Europe Diabetic Neuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Diabetic Neuropathy Market Size by Country (2019-2024)
7.4 Europe Diabetic Neuropathy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Neuropathy Market Size (2019-2030)
8.2 Asia-Pacific Diabetic Neuropathy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Diabetic Neuropathy Market Size by Region (2019-2024)
8.4 Asia-Pacific Diabetic Neuropathy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diabetic Neuropathy Market Size (2019-2030)
9.2 Latin America Diabetic Neuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Diabetic Neuropathy Market Size by Country (2019-2024)
9.4 Latin America Diabetic Neuropathy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Neuropathy Market Size (2019-2030)
10.2 Middle East & Africa Diabetic Neuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Diabetic Neuropathy Market Size by Country (2019-2024)
10.4 Middle East & Africa Diabetic Neuropathy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Diabetic Neuropathy Introduction
11.1.4 Pfizer Revenue in Diabetic Neuropathy Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Company Detail
11.2.2 Janssen Pharmaceuticals Business Overview
11.2.3 Janssen Pharmaceuticals Diabetic Neuropathy Introduction
11.2.4 Janssen Pharmaceuticals Revenue in Diabetic Neuropathy Business (2019-2024)
11.2.5 Janssen Pharmaceuticals Recent Development
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Detail
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Diabetic Neuropathy Introduction
11.3.4 Eli Lilly and Company Revenue in Diabetic Neuropathy Business (2019-2024)
11.3.5 Eli Lilly and Company Recent Development
11.4 ACTAVIS
11.4.1 ACTAVIS Company Detail
11.4.2 ACTAVIS Business Overview
11.4.3 ACTAVIS Diabetic Neuropathy Introduction
11.4.4 ACTAVIS Revenue in Diabetic Neuropathy Business (2019-2024)
11.4.5 ACTAVIS Recent Development
11.5 Cephalon
11.5.1 Cephalon Company Detail
11.5.2 Cephalon Business Overview
11.5.3 Cephalon Diabetic Neuropathy Introduction
11.5.4 Cephalon Revenue in Diabetic Neuropathy Business (2019-2024)
11.5.5 Cephalon Recent Development
11.6 MEDA Pharma & Co. KG
11.6.1 MEDA Pharma & Co. KG Company Detail
11.6.2 MEDA Pharma & Co. KG Business Overview
11.6.3 MEDA Pharma & Co. KG Diabetic Neuropathy Introduction
11.6.4 MEDA Pharma & Co. KG Revenue in Diabetic Neuropathy Business (2019-2024)
11.6.5 MEDA Pharma & Co. KG Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Detail
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Diabetic Neuropathy Introduction
11.7.4 GlaxoSmithKline Revenue in Diabetic Neuropathy Business (2019-2024)
11.7.5 GlaxoSmithKline Recent Development
11.8 NeuroMetrix
11.8.1 NeuroMetrix Company Detail
11.8.2 NeuroMetrix Business Overview
11.8.3 NeuroMetrix Diabetic Neuropathy Introduction
11.8.4 NeuroMetrix Revenue in Diabetic Neuropathy Business (2019-2024)
11.8.5 NeuroMetrix Recent Development
11.9 Johnson & Johnson Services, Inc.
11.9.1 Johnson & Johnson Services, Inc. Company Detail
11.9.2 Johnson & Johnson Services, Inc. Business Overview
11.9.3 Johnson & Johnson Services, Inc. Diabetic Neuropathy Introduction
11.9.4 Johnson & Johnson Services, Inc. Revenue in Diabetic Neuropathy Business (2019-2024)
11.9.5 Johnson & Johnson Services, Inc. Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Detail
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG Diabetic Neuropathy Introduction
11.10.4 Novartis AG Revenue in Diabetic Neuropathy Business (2019-2024)
11.10.5 Novartis AG Recent Development
11.11 DAIICHI SANKYO
11.11.1 DAIICHI SANKYO Company Detail
11.11.2 DAIICHI SANKYO Business Overview
11.11.3 DAIICHI SANKYO Diabetic Neuropathy Introduction
11.11.4 DAIICHI SANKYO Revenue in Diabetic Neuropathy Business (2019-2024)
11.11.5 DAIICHI SANKYO Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Pfizer
Janssen Pharmaceuticals
Eli Lilly and Company
ACTAVIS
Cephalon
MEDA Pharma & Co. KG
GlaxoSmithKline
NeuroMetrix
Johnson & Johnson Services, Inc.
Novartis AG
DAIICHI SANKYO
*If Applicable.